GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update

GlycoMimetics, Inc. (NASDAQ:GLYC) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 2,030,000 shares, a decrease of 9.4% from the January 15th total of 2,240,000 shares. Based on an average trading volume of 890,600 shares, the short-interest ratio is currently 2.3 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on GlycoMimetics in a report on Tuesday. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. VR Adviser LLC bought a new position in GlycoMimetics in the fourth quarter valued at $747,000. Jefferies Financial Group Inc. bought a new position in GlycoMimetics in the fourth quarter valued at $106,000. Caxton Corp bought a new position in shares of GlycoMimetics during the fourth quarter valued at about $51,000. Adage Capital Partners GP L.L.C. bought a new position in shares of GlycoMimetics during the fourth quarter valued at about $1,268,000. Finally, ADAR1 Capital Management LLC grew its stake in shares of GlycoMimetics by 626.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 286,127 shares during the last quarter. Institutional investors own 75.19% of the company’s stock.

GlycoMimetics Stock Performance

NASDAQ:GLYC opened at $0.29 on Tuesday. The stock’s fifty day moving average price is $0.26 and its two-hundred day moving average price is $0.24. GlycoMimetics has a 1 year low of $0.14 and a 1 year high of $3.36.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05.

About GlycoMimetics

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.